metricas
covid
Buscar en
Clínica e Investigación en Ginecología y Obstetricia
Toda la web
Inicio Clínica e Investigación en Ginecología y Obstetricia Papel de la trombocitosis en el adenocarcinoma de endometrio
Información de la revista
Vol. 29. Núm. 8.
Páginas 290-295 (enero 2002)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. 8.
Páginas 290-295 (enero 2002)
Acceso a texto completo
Papel de la trombocitosis en el adenocarcinoma de endometrio
Visitas
6924
M. Sánchez, J.V. Torres
Departamento de Pediatría, Obstetricia y Ginecología. Facultad de Medicina y Odontología. Valencia. España.
Este artículo ha recibido
Información del artículo
Resumen

Es conocida la asociación entre neoplasia maligna y trombocitosis. En el presente trabajo se analiza la prevalencia de esta condición en el adenocarcinoma de endometrio, su relación con otros factores y su impacto pronóstico. Se estudiaron 499 casos, comparando el número de plaquetas con la edad, la paridad, elintervalo fértil, la duración de la sintomatología, el retraso terapéutico, los marcadores tumorales CA125, CA153, CA199 y CEA, la estadificación de la FIGO, la histología y el grado tumorales, y la invasión miometrial. Asimismo, se analizó el impacto pronóstico de la trombocitosis. Tomando como punto de corte unnúmero de plaquetas de 300.000/μl (hiperplaquetosis), se observaron cifras significativamente más elevadas de CA125, CA153 y CEA. Tomando como punto de corte 400.000 trombocitos/μl (trombocitosis), se observó mayor duración de la sintomatología previa a la consulta en los casos de trombocitosis, y cifras significativamente más elevadas de CEA; se observaron también diferencias significativas en cuanto al estadio FIGO, el grado tumoral y la invasión miometrial. Se obtuvieron diferencias estadísticamente significativas en las tasas de supervivencia según la cifra de plaquetas.

Summary

The association between malignant neoplasm and thrombocytosis is well known. In this work is analysed the prevalence of this condition in adenocarcinoma of the endometrium, its relationship with other factors, and its prognostic impact. A study of 499 cases was made, comparing the number of platelets with age, parity, fertile interval, duration of symptoms, therapeutic delay, tumour markers Ca 125, Ca 153, Ca 199 and CEA, FIGO stage, histology, tumoral grade, and myometrial invasion an also, the prognostic impact of thrombocytosis. Taking as a cut off point 300,000 platelets per microlitre significantly more elevated levels of Ca 125, Ca 153, and CEA were observed. Taking as a cut off point 400,000 platelets per microlitre, it was observed that there was a longer period of symptomatology prior to consultation in the thrombocytosis cases, and significantly more elevated levels of CEA: there were also significant differences in both the FIGO stage, tumour grade, and myometrial invasion. Statistically significant differences were found in levels of survival, depending on the number of platelets.

El Texto completo está disponible en PDF
Bibliografía
[1.]
L. Riess.
Zur pathologischen Anatomie des Blutes.
Arch Anat Physiol Wissennsch Med, 39 (1972), pp. 237-249
[2.]
V. Costantini, L.R. Zacharski, T.E. Moritz, R.L. Edwards.
The platelet count in carcinoma of the lung and colon.
Thromb Haemost, 64 (1990), pp. 501-505
[3.]
L. Moller-Pedersen, N. Milman.
Prognostic significance of thrombocytosis in patients with primary lung cancer.
Eur Respir J, 9 (1996), pp. 1826-1830
[4.]
T. Nakano, J. Fujii, S. Tamura, T. Hada, K. Higashino.
Throm-bocytosis in patients with mallignant mesothelioma.
Cancer, 58 (1986), pp. 1699-1701
[5.]
J. Menczer, D. Geva, E. Schejter, H. Zakut.
Elevated platelet count in patients with endometrial carcinoma: correlation with selected prognostic factors and with survival.
Int J Gy-necol Cancer, 6 (1996), pp. 463-466
[6.]
G.C. Rodríguez, D.L. Clarke-Pearson, J.T. Soper, A. Berhuck, I. Synan, R.K. Dodge.
The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer.
Obstet Gynecol, 83 (1994), pp. 445-448
[7.]
E. Hernández, M. Lavine, C.J. Dunton, E. Gracely, J. Parker.
Poor prognosis associated with thrombocytosis in patients with cervical cancer.
Cancer, 69 (1992), pp. 2975-2977
[8.]
A.G. Zeimet, C. Marth, E. Muller-Holzner, G. Daxenbichler, O. Dapunt.
Significance of thrombocytosis in patients with epithelial ovarian cancer.
Am J Obstet Gynecol, 170 (1994), pp. 549-554
[9.]
E. Hernández, P. Heller, C. Withney, K. Diana, G. Delgado.
Thrombocytosis in surgically treated stage IB squamous cell cervical carcinoma (a Gynecologic Oncology Group study.
Gynecol Oncol, 55 (1994), pp. 328-332
[10.]
A. Lopes, V. Daras, P.A. Cross, G. Robertson, G. Beynon, J.M. Mo-naghan.
Thrombocytosis as a prognostic factor in women with cervical cancer.
Cancer, 74 (1994), pp. 90-92
[11.]
G. Corbet, D.J. Perry.
Significance of thrombocytosis.
Lancet, I (1983), pp. 77
[12.]
J.A. Dutcher.
Hematologic abnormalities in patients with nonhematologic malignancies.
Hematol Oncol Clin North Am, I (1987), pp. 281-289
[13.]
R.L. Edwards, F.R. Rickles, T.E. Moritz, W.G. Henderson, L.R. Za-charski, W.B. Forman, et al.
Abnormalities of blood coagulation tests in patients with cervical cancer.
Am J Clin Pathol, 88 (1988), pp. 596-602
[14.]
G. Gastl, M. Plante, C.L. Finstad, G.Y. Wong, M.G. Federici, N.H. Bander, et al.
High IL 6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer.
Br J Haematol, 83 (1993), pp. 433-441
[15.]
N.H. Obata, K. Tamakoshi, K. Shibata, F. Kikkawa, Y. Tomoda.
Effects of interleukin 6 on in vitro cell attachment, migration, and invasion of human ovarian carcinoma.
Anticancer Res, 17 (1997), pp. 337-342
[16.]
A. Erroi, M. Sironi, F. Chiaffarino, A. Zhen-Guo, M. Mengozzi, A. Mantovani.
IL 1 and IL-6 release by tumor-associated macrophages from human ovarian carcinoma.
Int J Cancer, 44 (1989), pp. 795-801
[17.]
Z. Estrov, M. Talpaz, G. Mavligit, D. Pazdur, D. Harris, S.M. Gre-enberg, et al.
Elevated plasma thrombopoietic activity in patients with metastatic cancer related thrombocytosis.
Am J Med, 98 (1995), pp. 551-558
[18.]
T. Imai, K. Koike, T. Kubi, T. Kikuchi, Y. Amano, N. Okumuro, et al.
Interleukina-6 supports human megakaryo-cyte proliferation and differentiation in vitro.
Blood, 78 (1991), pp. 1969-1974
[19.]
T. Ishibashi, H. Kimura, Y. Shikama, T. Uchida, S. Kariyone, T. Hirano, et al.
Interleukin 6 is a potent thrombopoietic factor in vivo in mice.
Blood, 74 (1989), pp. 1241-1244
[20.]
J.S. Berek, C. Chung, K. Kaldi, J.M. Whatson, R.M. Knox, O. Martínez-Maza.
Serum interleukin 6 levels correlate with disease status in patients with epithelial ovarian cancer.
Am J Obstet Gynecol, 164 (1991), pp. 1038-1044
[21.]
G. Scambia, U. Testa, P. Benedetti-Panici, E. Foti, R. Martucci, A. Gadducci, et al.
Prognostic significance of interleukin-6 serum levels in patients with ovarian cancer.
Br J Cancer, 71 (1995), pp. 354-357
[22.]
V. Chopra, T.V. Dinh, E.V. Hanningan.
Serum levels of inter-leukins, growth factors and angiogenin in patients with endo-metrial cancer.
J Cancer Res Clin Oncol, 123 (1997), pp. 167-172
[23.]
K.V. Honn, D.G. Tang, J.D. Crissman.
Platelets and cancer metastasis: a causal relationship.
Cancer Metastasis Rev, 11 (1992), pp. 325-341
[24.]
H. Boukerche, O Tabone E Berthier-Vergnes, M. Bailly, J.F. Dore, J.L. McGregor.
Thrombospondin modulates melanomaplatelet interactions and melanoma tumor cell growth in vivo.
Br J Cancer, 72 (1995), pp. 108-116
[25.]
V.S. Zabrenetzky, E.C. Kohn, D.D. Roberts.
Suramin inhibits laminin and thrombospondin-mediated melanoma cell adhesion and migration and binding of these adhesive proteins to sulfatide.
Cancer Res, 50 (1990), pp. 5937-5942
[26.]
T.C. Everson, W.H. Cole.
Spontaneous regression of cancer.
[27.]
R. Parker, D. Lanvin, B. Gilks, D. Miller.
Spontaneous regression of stage IV clear cell carcinoma of the endometrium in a patient with essential trombocitosis.
Gynecol Oncol, 82 (2001), pp. 395-399
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos